A common diabetes medication is moving closer to becoming an eye drop treatment for serious retinal diseases. The U.S. Patent and Trademark Office (USPTO) has approved a patent for topical metformin formulations designed to treat age-related macular degeneration (AMD), Stargardt disease, and other forms of retinal degeneration. This approval represents a significant step toward bringing a new therapeutic option to patients who currently have limited treatment choices for these vision-threatening conditions.

What Diseases Could This Eye Drop Treat?

The allowed patent claims cover several serious retinal conditions that affect millions of people worldwide. Metformin, delivered as an eye drop rather than a pill, is being developed to address multiple forms of retinal damage that progressively steal vision. The conditions included in the patent allowance are:

• Age-Related Macular Degeneration (AMD): A leading cause of vision loss in older adults that damages the macula, the part of the retina responsible for sharp central vision.
• Retinal Pigment Epithelium Degeneration: Damage to the supportive layer beneath the retina that nourishes light-sensitive cells.
• Stargardt Disease: A rare inherited condition that causes progressive vision loss, typically beginning in childhood or young adulthood.
• Stargardt-Like Disease: Similar vision loss patterns that may have different underlying causes than classic Stargardt disease.

These conditions represent some of the most challenging eye diseases to treat. AMD alone affects roughly 11 million Americans, making it the leading cause of vision loss in people over 50. The fact that metformin, a medication already familiar to millions of diabetes patients, could be reformulated as an eye drop offers hope for a more accessible treatment approach.

How Did This Patent Approval Happen?

The technology behind this eye drop treatment originated at the National Eye Institute (NEI), part of the National Institutes of Health (NIH). Dr. Kapil Bharti and colleagues at the NEI developed the therapeutic approach, which was then licensed exclusively to Curative Biotechnology. The company has been working to advance this metformin-based therapy toward human testing.

The patent allowance, U.S. Patent Application No. 17/642,610, titled "Druggable Target to Treat Retinal Degeneration," follows a previously announced patent approval in Canada. This dual approval strengthens the intellectual property protection for the technology and signals confidence in its potential clinical value.

"This U.S. patent allowance represents another important milestone in strengthening our intellectual property portfolio around our metformin-based ophthalmic therapies," said Paul Michaels, executive chairman of Curative Biotechnology.

Paul Michaels, Executive Chairman at Curative Biotechnology

What Steps Are Being Taken to Bring This to Patients?

The patent approval is just one piece of a larger development strategy. Curative Biotechnology has announced several parallel efforts to move the treatment closer to human use:

• Manufacturing Agreement: The company has secured a manufacturing agreement to produce the eye drop formulation at scale, a critical step before clinical trials can begin.
• Research Collaboration: A translational research partnership with the University of Pennsylvania's School of Veterinary Medicine is underway to test the therapy in animal models before human studies.
• Clinical Study Planning: A Cooperative Research and Development Agreement (CRADA) with the National Eye Institute is supporting the design of a planned first-in-human clinical study, which would be the first test of this treatment in actual patients.

These coordinated efforts suggest the company is moving methodically through the development pipeline. Animal testing and manufacturing readiness typically precede human clinical trials by months to years, so patients should not expect immediate availability. However, the combination of patent protection, manufacturing capability, and planned clinical research indicates serious momentum toward bringing this therapy to market.

Why Does Metformin in Eye Drop Form Matter?

Metformin is one of the world's most widely prescribed medications for type 2 diabetes, with decades of safety data in humans. Reformulating it as a topical eye drop rather than an oral tablet could offer several advantages. Eye drops deliver medication directly to the retina with potentially lower systemic side effects, and patients already familiar with metformin may feel more confident about its safety profile. Additionally, the drug's mechanism of action in the retina appears to target a specific pathway involved in retinal cell degeneration, offering a novel approach to diseases that currently have few effective treatments.

For patients with AMD, Stargardt disease, or retinal pigment epithelium degeneration, the current treatment landscape is limited. Some forms of AMD have injectable therapies, but these require frequent office visits and can be expensive. A topical eye drop would be far more convenient and potentially more accessible. The patent approval suggests that regulatory and scientific experts believe this approach has genuine merit.

While the patent allowance is encouraging news, patients should understand that clinical trials still lie ahead. The first-in-human study will determine whether the eye drop formulation is safe and effective in actual patients. However, this milestone represents a concrete step forward in bringing a new treatment option to millions of people living with vision-threatening retinal diseases.